Maze Therapeutics Inc (MAZE) Quarterly Institutional 13F Update (Q2 2026)

MAZE ranks #3466 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MAZE is a top-conviction position for Trv Gp Iv, LLC — at 52.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MAZE belongs to Frazier Life Sciences Management, L.P., but the position matters far more to Trv Gp Iv, LLC, who has 52.6% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

JPMorgan has added to its MAZE position for two straight quarters, increasing it by $27.2M to reach $28.0M today.

Trv Gp Iv, LLC has trimmed its MAZE position for two straight quarters, cutting it by $51.9M while still holding $133.5M.

MAZE is down 3.2% today, but institutions show net buying of $386.1M this quarter — a divergence between today's price move and the underlying institutional flow.

MAZE reported a net loss of $133.6M over the trailing twelve months.

• Not yet profitable — net loss of $133.6M over the trailing twelve months
• Revenue declined 88.1% year over year
• Net income declined year over year, from -$120.8M to -$133.6M
• Operating cash flow was negative, using $111.9M in cash
• Current ratio of 15.50x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range